Price
No data yet.
Social Signal Score
Analyst Ratings
53 analystsRevenue
$1.34B+685.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Steven Leach
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 11,050
- Beta
- 1.44
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 7.45
Financials
Revenue
$1.34B+685.3%Net Income
$275.10MEBITDA
$412.30MFree Cash Flow
$272.70MEPS (diluted)
$0.72Shares Outstanding (diluted)
383.50M+13.3%Operating Expenses
$537.20MCash & Debt
$1.82BReturn of Capital
$400.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.66B | $836.30M | $2.14 |
| 2024 | $4.03B | $576.20M | $1.46 |
| 2023 | $3.62B | $541.50M | $1.44 |
| 2022 | $2.91B | $341.20M | $0.88 |
| 2021 | $2.45B | $216.90M | $0.56 |
| 2020 | $1.93B | $493.60M | $1.31 |
| 2019 | $1.48B | $101.10M | $0.28 |
| 2018 | $1.03B | $-127.10M | $-0.36 |
| 2017 | $718.50M | $-50.20M | $-0.15 |
| 2016 | $573.30M | $-65.60M | $-0.20 |
| 2015 | $402.00M | $-57.60M | $-0.18 |
| 2014 | $259.20M | $-22.40M | $-0.07 |
| 2013 | $160.00M | $-29.80M | $-0.10 |
| 2012 | $99.90M | $-54.50M | $-0.20 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.15
- Implied price
- $97.62
- Return from $82.27
- 3.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $48.54 — -41.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| -2.0% | -13.1% | -9.3% | -6.1% | -3.2% | -0.7% |
| 3.0% | -8.7% | -4.7% | -1.3% | 1.7% | 4.4% |
| 8.0% | -4.3% | -0.1% | 3.5% | 6.6% | 9.4% |
| 13.0% | 0.2% | 4.5% | 8.3% | 11.6% | 14.5% |
| 18.0% | 4.6% | 9.2% | 13.1% | 16.5% | 19.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (37)
- Newsbusinesswire.com·3d ago·Positive
Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone ATHENRY, Ireland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today officially opened its state-of-the-art manufacturing facility in Athenry, County Galway, marking a major milestone in the company's investment in Ireland and its manufacturing presence in Europe, the Middle East and Africa. The official opening ceremony, attended by Minister for Public Expenditure,…
View source ↗ - Newsseekingalpha.com·5d ago·Positive
DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newszacks.com·9d ago·Positive
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now DexCom's G7 15 Day adoption, international expansion and margin gains support its growth prospects, though competition and rising investments pose challenges.
View source ↗ - News (RSS)fortune·15d ago·Neutral
He went from washing lab equipment for $10 an hour to leading a $30 billion healthcare company. His advice to Gen Z: Raise your hand Dexcom CEO Jake Leach says the secret to getting ahead isn't asking for a promotion—it's becoming the person willing to take on what others won't.
View source ↗ - Newszacks.com·19d ago·Positive
DexCom to Launch 15-Day G7 CGM System in Canada This November DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.
View source ↗ - News (RSS)seekingalpha·20d ago·Neutral
DexCom, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
DexCom: Improving Patient Access Makes It A Long-Term Buy
View source ↗ - Newsseekingalpha.com·20d ago·Positive
DexCom: Improving Patient Access Makes It A Long-Term Buy DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.
View source ↗ - Newszacks.com·23d ago·Positive
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
View source ↗ - News (RSS)investing·24d ago·Neutral
Why is DexCom stock climbing today?
View source ↗ - Newsseekingalpha.com·24d ago·Positive
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Positive
What DexCom (DXCM) Said on Its Q3 Earnings Call DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.
View source ↗ - Newszacks.com·24d ago·Positive
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.
View source ↗ - Newsbenzinga.com·24d ago·Positive
DexCom Q3 2026 Earnings Call Transcript DexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
View source ↗ - News (RSS)financialpost·25d ago·Positive
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November The longest-lasting and most accurate1 continuous glucose monitoring (CGM) system authorized by Health Canada will offer people living with diabetes over the age of 18 up to 15.5 days of wear with fewer sensor changes.2 Dexcom G7 15 Day will be publicly reimbursed for many eligible Canadians living with diabetes beginning in November. Private health […]
View source ↗ - Newszacks.com·27d ago·Neutral
DexCom Gears Up to Report Q3 Results: How to Play the Stock? DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
View source ↗ - News (RSS)seekingalpha·35d ago·Negative
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives
View source ↗ - Newsseekingalpha.com·35d ago·Negative
…nufacturing costs, driving Q2 2026 gross margin up 400 bps to 64.1% and enabling 70% incremental operating margins. CONNECT study results published in NEJM reinforce DXCM's clinical leadership, particularly among GLP-1 users, supporting expanded coverage and future growth.
View source ↗ - News (Marketaux)gurufocus.com·37d ago·Positive
A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 On October 15, 2026, DexCom <em[+319 characters]
View source ↗ - Newsreuters.com·38d ago·Neutral
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
View source ↗ - Newsbusinesswire.com·39d ago·Negative
…The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on in…
View source ↗ - Newszacks.com·40d ago·Positive
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
View source ↗ - News (Marketaux)gurufocus.com·41d ago·Positive
DXCM Maintains Buy Rating by BTIG -- Price Target Raised to $96.00 On October 12, 2026, BTIG analyst Ryan Z[+139 characters]
View source ↗ - Newszacks.com·51d ago·Neutral
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
View source ↗ - Newszacks.com·54d ago·Positive
Here's Why DexCom (DXCM) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsbusinesswire.com·69d ago·Neutral
Dexcom Promotes Jereme Sylvain to Chief Operating Officer SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
View source ↗ - Newszacks.com·69d ago·Positive
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·81d ago·Positive
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·89d ago·Positive
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now? ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
View source ↗ - Newszacks.com·93d ago·Positive
Here's Why DexCom (DXCM) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)yahoo·100d ago·Neutral
Is Wall Street Bullish or Bearish on DexCom Stock?
View source ↗ - Newszacks.com·101d ago·Positive
Here's Why DexCom (DXCM) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·102d ago·Positive
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches? DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
View source ↗ - Newszacks.com·102d ago·Positive
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum? DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
View source ↗ - Newszacks.com·102d ago·Positive
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here? DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
View source ↗ - Newszacks.com·102d ago·Positive
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026? DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $0.71 per share
Typical surprise +8.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$0.73 vs $0.68beat
- Thu, Jul 30$0.70 vs $0.61beat
- Thu, Apr 30$0.56 vs $0.47beat
- Thu, Feb 12$0.68 vs $0.65beat
- Thu, Oct 30$0.61 vs $0.58beat
- Wed, Jul 30$0.48 vs $0.44beat
Estimates and results for DXCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DXCM officers and directors.
- Bought
- $1.0m
- Sold
- $13.8m
2 trades
38 trades
- Stern Sadiesold
- Brown Michael Jonsold
- Stern Sadiesold
- Augustinos Nicholassold
- Brown Michael Jonsold
- Augustinos Nicholassold
- Sylvain Jereme Msold
- Stern Sadiesold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- John Boozmansenate · AR · disclosed Feb 15, 2026 (20d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 9, 2025 (37d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 9, 2025 (23d later)Sell$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (46d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed May 15, 2025 (37d later)Buy$50,001 - $100,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Sell$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2025 (36d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Jan 15, 2025 (15d later)Sell$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
